费尔蒂综合征的生物治疗与严重的中性质减退症
Krzysztof Proc1, Marta Madej2, Piotr Wiland2
1Department of Rheumatology and Internal Medicine, Medical University Hospital, Wroclaw, Poland.
Reumatologia
|July 31, 2023
概括
费尔蒂综合征是一种涉及类风湿性关节炎,脏膨胀和低白细胞计数的疾病,可用疾病修饰性抗风湿药物 (DMARD) 治疗. 本案例研究探讨了Felty综合征的生物DMARDs,强调了潜在的并发症和管理策略.
科学领域:
- 类风湿病学 类风湿病学
- 血液学 血液学 血液学
背景情况:
- 费尔蒂综合征是由血清阳性类风湿性关节炎 (RA),壮症和中性衰竭的三位一体定义的.
- 目前针对费尔蒂综合征的治疗策略主要涉及疾病修饰性抗风湿药物 (DMARDs),包括常规合成和生物药物.
研究的目的:
- 介绍一个用生物疗法治疗费尔蒂综合征的案例研究.
- 审查费尔蒂综合征中性质减退症的诊断,区分和管理.
- 讨论Felty综合征的当前治疗选择,包括经典和生物DMARDs.
主要方法:
- 电子医学数据库的系统文献搜索.
- 一个患有费尔蒂综合征的患者接受生物治疗的案例介绍.
主要成果:
- 改变疾病的抗风湿药物 (DMARDs) 可以减少疾病的活性,但可能导致显著的临床并发症.
- 中性和发烧性中性是费尔蒂综合征管理中的关键考虑因素.
结论:
- 生物治疗是一种治疗费尔蒂综合征的治疗选择.
- 在治疗费尔蒂综合征的DMARD治疗期间,对中性衰竭的仔细监测和管理至关重要.
- 了解经典和生物DMARDs的全方位治疗可能性对于最佳的患者护理至关重要.
相关概念视频
Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...
Calcium Ion Concentration Mechanism
If over time, all...
Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...


